Public Health and Economic Impact of RSVpreF Vaccination Among Older Adults in Latin America and the Caribbean
Author(s)
Rengina Kefalogianni, MSc1, Juan José Baldi-Castro, MSc, PharmD2, Julia Spinardi, MD, MSc3, Diana Mendes, PhD1, Reiko Sato, PhD4.
1Pfizer Ltd., Tadworth, United Kingdom, 2Pfizer Inc., Escazú, Costa Rica, 3Pfizer, São Paulo, Brazil, 4Pfizer Inc., Collegeville, PA, USA.
1Pfizer Ltd., Tadworth, United Kingdom, 2Pfizer Inc., Escazú, Costa Rica, 3Pfizer, São Paulo, Brazil, 4Pfizer Inc., Collegeville, PA, USA.
Presentation Documents
OBJECTIVES: This study assessed the burden of respiratory syncytial virus (RSV) among adults aged ≥60 years and the impact of RSVpreF vaccination in Argentina, Brazil, Chile, Mexico, the Central America and the Caribbean (CAC) and the Pan American Health Organization (PAHO) regions.
METHODS: A Markov model was used to project the lifetime outcomes of RSV among adults, including RSV-related hospitalizations, emergency department (ED) visits, outpatient visits, deaths, and associated direct medical costs. Inputs were derived from publicly available epidemiological, uptake (existing programmes range 44-93%), and cost (2024 US$) data. Vaccine effectiveness was based on RENOIR trial with linear extrapolation of waning beyond trial data.
RESULTS: Without vaccination, over the cohort lifetime, RSV was projected to cause 25.7 million (M) medically-attended cases in Brazil (2.4M hospitalizations), 12.9M in Mexico (1.2M hospitalizations), 3.4M in Argentina (109,858 hospitalizations), and 3.2M in Chile (64,440 hospitalizations), with associated direct medical costs of 3.3 billion (B), 4.3B, 208M , and 251M, respectively. In the CAC and PAHO regions, RSV was estimated to cause 20.9M cases (1.6M hospitalisations) and 107.2M cases (6.7M hospitalisations), respectively, with associated direct medical costs of US$9.5B and US$20.2B. With RSVpreF vaccination (single dose), 2M cases would be prevented—1.3M in Brazil (181,943 hospitalizations), 443,145 in Mexico (65,679 hospitalizations), 128,883 in Argentina (5,531 hospitalizations), and 197,027 in Chile (5,244 hospitalizations)—leading to an estimated US$311M, US$361M, US$13.77M, and US$26.68 in direct medical costs averted, respectively. In the CAC and PAHO regions, vaccination was projected to prevent 484,698 and 4.9M cases, respectively (61,979 and 428,635 hospitalizations), with corresponding cost savings of US$572M and US$1.5B.
CONCLUSIONS: RSV places a substantial health and economic burden on older adults in Latin America and the Caribbean. The introduction of RSVpreF vaccination is anticipated to reduce this burden by preventing a large number of cases and death while lowering medical expenditures.
METHODS: A Markov model was used to project the lifetime outcomes of RSV among adults, including RSV-related hospitalizations, emergency department (ED) visits, outpatient visits, deaths, and associated direct medical costs. Inputs were derived from publicly available epidemiological, uptake (existing programmes range 44-93%), and cost (2024 US$) data. Vaccine effectiveness was based on RENOIR trial with linear extrapolation of waning beyond trial data.
RESULTS: Without vaccination, over the cohort lifetime, RSV was projected to cause 25.7 million (M) medically-attended cases in Brazil (2.4M hospitalizations), 12.9M in Mexico (1.2M hospitalizations), 3.4M in Argentina (109,858 hospitalizations), and 3.2M in Chile (64,440 hospitalizations), with associated direct medical costs of 3.3 billion (B), 4.3B, 208M , and 251M, respectively. In the CAC and PAHO regions, RSV was estimated to cause 20.9M cases (1.6M hospitalisations) and 107.2M cases (6.7M hospitalisations), respectively, with associated direct medical costs of US$9.5B and US$20.2B. With RSVpreF vaccination (single dose), 2M cases would be prevented—1.3M in Brazil (181,943 hospitalizations), 443,145 in Mexico (65,679 hospitalizations), 128,883 in Argentina (5,531 hospitalizations), and 197,027 in Chile (5,244 hospitalizations)—leading to an estimated US$311M, US$361M, US$13.77M, and US$26.68 in direct medical costs averted, respectively. In the CAC and PAHO regions, vaccination was projected to prevent 484,698 and 4.9M cases, respectively (61,979 and 428,635 hospitalizations), with corresponding cost savings of US$572M and US$1.5B.
CONCLUSIONS: RSV places a substantial health and economic burden on older adults in Latin America and the Caribbean. The introduction of RSVpreF vaccination is anticipated to reduce this burden by preventing a large number of cases and death while lowering medical expenditures.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH197
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines